Affordable Insulin Approvals Now Act
This bill requires the continued review and approval, as appropriate, of certain pending applications for generic insulin beyond the March 23, 2020, cutoff date previously established by the Food and Drug Administration. Beginning March 23, 2020, these approved generic insulin drugs also are deemed licensed biological products.